Genmab — August 2014
-
Data from the Phase III study of ofatumumab in combination with fludarabine and cyclophosphamide
versus fludarabine and cyclophosphamide in relapsed CLL was also expected to be reported in 2014.
The timing of the results of this study is based on a predefined number of patients in the study
experiencing worsening of their disease. The timeline for reporting results for this study has been revised
as patients in the study are living longer without their disease getting worse. -
ja
-
allerede igang i tyskalnd i juli
-
nok med bendamustine
-
det er som det skal være
-
deutsche gode spørgsmål
-
daratumumab er det mest vigtige stof i hele J&J development siger jannsen
-
de har massiv entusiasme in house for det pt
-
han sagde direkte at det er det mest hotte in house produkt hos J&J pt
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind